Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum-pNZ44-Oxyntomodulin
- Development stage
- Preclinical
- Lead developer
- Hangzhou, China
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum-pNZ44-Oxyntomodulin (Bl-OXM) is an engineered live biotherapeutic product designed for the oral delivery of oxyntomodulin (OXM). OXM is a gut hormone that acts as a dual agonist for the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). This therapeutic candidate utilizes a specific probiotic strain, *Bifidobacterium longum* (ATCC15707), as a carrier transformed with the pNZ44-OXM expression vector. Developed by researchers in Hangzhou, China, Bl-OXM is primarily investigated for the treatment of painful diabetic neuropathy (PDN). Preclinical studies have demonstrated that oral administration of Bl-OXM can alleviate pain, reverse nerve fiber lesions, and restore neuronal hyperexcitability by regulating gut microbiota homeostasis and inhibiting the TLR4/MyD88/NF-κB proinflammatory signaling pathway in the sciatic nerve.
- Other names
- Bifidobacterium longum-pNZ44-OXMengineered Bifidobacterium longum expressing oxyntomodulin
02
Targets
GLP1R (GLP-1R)GCGR (Glucagon receptor)
Beyond the preview
Go deeper on Bifidobacterium longum-pNZ44-Oxyntomodulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum-pNZ44-Oxyntomodulin.